



## **EuroSIDA Study Group**

### **Contact**

EuroSIDA Study Group

## Publications (4)

Laut K, Schmid P, Kuzovatova E, Paduta D, Smidt J, Domingo P, Szlávik J, Lundgren J, Mocroft A, Kirk O, Mulcahy F, Fätkenheuer G, Ristola M, Shepherd L, Gottfredsson M, Sedlacek D, Knysz B, Begovac J, Radoi R, Schmied B, Chkhartishvili N, Florence E, EuroSIDA Study Group. Variation in antiretroviral treatment (ART) coverage and virological suppression among three HIV key populations. *AIDS* 2018

Santos J, Gargalianos-Kakolyris P, Schmid P, Hassoun G, Khromova I, Beniowski M, Hadziosmanovic V, Sedlacek D, Paredes R, Lundgren J, Bogner J, Duvivier C, Cozzi-Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A, Sluzhynska M, Orkin C, EuroSIDA Study Group. Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe. *HIV Med* 2018; 19:324-338.

Cozzi-Lepri A, Khromova I, Jilich D, Flisiak R, Smidt J, Rozentale B, Radoi R, Losso M, Lundgren J, Mocroft A, Gottfredsson M, Schmid P, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H, Fätkenheuer G, Yust I, EuroSIDA Study Group. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. *HIV Med* 2017

Phillips A, Frankfurt HIV Clinic Cohort, Swiss HIV Cohort Study, Ledergerber B, Lundgren J, Vernazza P, Miller V, Francioli P, Kirk O, Weber R, Staszewski S, EuroSIDA Study Group. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. *JAMA : the journal of the American Medical Association* 2001; 286:2560-7.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)